Elsevier

Molecular Immunology

Volume 32, Issues 17–18, December 1995, Pages 1377-1385
Molecular Immunology

Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells, by increasing the lifespan of both free and MHC-complexed peptides

https://doi.org/10.1016/0161-5890(95)00103-4Get rights and content

Abstract

We investigated the effect of modifying the N- and/or C-termini of the snake toxin peptide 24–36 on its presentation to T cells. Acetylation at the N-terminus as well as amidation at the C-terminus enhanced the capacity of the peptide to activate T cells. Simultaneous modifications further increased the stimulating activity, the peptide becoming approximately 100-fold more potent than the unmodified peptide. Clearly, the introduced modifications increased the lifetime of the peptide free in solution, by decreasing its proteolytic degradation, during the T cell stimulation assays. Paradoxically, however, at similar concentrations of free peptides, the modified ones, especially those having an acetylated N-terminus, were much more active than the unmodified peptide, irrespective of the experimental conditions. These observations suggested that components other than protection from proteolytic degradation should be associated with the higher stimulating activities of the modified peptides. Accordingly, chasing experiments with APC revealed that acetylation at N-terminus caused a higher persistence of the peptides at APC surface. Together, our data indicate that (i) the T cell stimulating capacity of a peptide is associated with its lifespans in the free and MHC II bound states; and (ii) these lifespans can be greatly enhanced by introducing fine chemical modifications at N- and C-termini. These data may have some implications in designing more potent peptidic immunomodulators.

References (47)

  • L.D. Falo et al.

    Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules

  • D.H. Fremont et al.

    Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb

    Science

    (1992)
  • A.S. Hansen et al.

    A mouse aminopeptidase N is a marker for antigen-presenting cells and appears to be co-expressed with Major histocompatibility complex class II molecules

    Eur. J. Immun.

    (1993)
  • C.V. Harding et al.

    Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T cell stimulation

    Nature

    (1990)
  • C.V. Harding et al.

    Turnover of Ia-peptide complexes is facilitated in viable antigen-presenting cells: biosynthetic turnover of Ia Vs peptide exchange

  • D.F. Hunt et al.

    Peptides presented to the immune system by the murine Class II Major Histocompatibility Complex molecule I-Ad

    Science

    (1992)
  • G.Y. Ishioka et al.

    Failure to demonstrate long-lived MHC saturation both in vitro and in vivo

    J. Immun.

    (1994)
  • T.S. Jardetzky et al.

    Identification of self peptides bound to purified HLA-B27

    Nature

    (1991)
  • J.L. Jorgensen et al.

    Molecular components of T cell recognition

    A. Rev. Immun.

    (1992)
  • S. Kozlowski et al.

    Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp 160 peptide for presentation by Major histocompatibility complex Class I molecules

    J. exp. Med.

    (1992)
  • H. Kropshofer et al.

    Self peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal proline as a stop signal for trimming

    J. Immun.

    (1993)
  • A.G. Lamont et al.

    The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo

    J. Immun.

    (1990)
  • A. Lanzavecchia et al.

    Irreversible association of peptides with class II MHC molecules in living cells

    Nature

    (1992)
  • Cited by (27)

    • Challenge to overcome current limitations of cell-penetrating peptides

      2021, Biochimica et Biophysica Acta - Proteins and Proteomics
      Citation Excerpt :

      For example, a tetrapeptide Arg-Leu-Tyr-Glu (RLYE) has a half-life of 1.2 h in serum due to the degradation by aminopeptidase B and N, but N-acetylation can elongate the half-life to 8.8 h [178]. Also, N-acetylation and C-amidation can significantly increase the stability of major histocompatibility complex (MHC)-binding peptides in serum [179,180]. This capping or amidation could simply be accomplished during SPPS of CPPs by performing a final acetylation step and selecting the appropriate resins [181,182].

    • Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain

      2007, Analytical Biochemistry
      Citation Excerpt :

      ESI and matrix-assisted laser desorption/ionization (MALDI) MS have shown that the conotoxin TxVIIA is C-terminally amidated [24], and α-amidation has been detected in recombinant peptides by ESI MS [25]. Evidence has also been published showing α-amidation to be a protective PTM against exopeptidase degradation [26,27]. In peptide hormones, amidation has been shown to influence bioactivity through a reduction of the net positive charge of the peptide and a change in its conformation [22].

    • Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA<inf>2</inf> as a membrane-binding vector

      2005, FEBS Letters
      Citation Excerpt :

      In contrast, the presentation of peptide N9V was not affected by BFA and the level of cell surface HLA-A2 was only slightly reduced. In addition, P30–34 was not presented by DCs fixed with glutaraldehyde, a treatment known to block intracellular processing but not extracellular processing [27], while the peptide was. uP30–34 was not presented by fixed or untreated DCs, showing also the absence of extracellular processing.

    View all citing articles on Scopus
    View full text